Canakinumab

Active substance
Canakinumab
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
Indication extension
Main indication
Lung cancer
Extended indication
Gevorderd niet-kleincellig longcarcinoom, als toevoeging aan pembrolizumab en chemotherapie

1. Product

Manufacturer
Novartis
Mechanism of action
Interleukin inhibitor
Route of administration
Subcutaneous
Therapeutical formulation
Injection liquid
Budgetting framework
Intermural (MSZ)

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
June 2021
Expected Registration
June 2022
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Voor niet-oncologische indicaties is canakinumab reeds op de markt onder de merknaam Ilaris.

3. Therapeutic value

Current treatment options
Pembrolizumab, nivolumab, atezolizumab, durvalumab.
Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
1 times every 3 weeks
References
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. doi: 10.21037/jtd.2018.07.50 NCT03631199
Additional comments
Op dit moment zijn er nog geen resultaten bekend. De gerandomiseerde fase 3 studie wordt gecompleteerd in medio 2022.

4. Expected patient volume per year

There is currently nothing known about the expected patient volume.

5. Expected cost per patient per year

References
FK
Additional comments
Prijs per injectieflacon €11.990.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
Behcet's syndrome; Pneumonia
References
adisinsight
Additional comments
Lopende fase 3 studies.

9. Other information

There is currently no futher information available.